share_log

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Dianthus Therapeutics將參加三個即將舉行的醫療投資者會議
GlobeNewswire ·  2024/11/04 12:00

NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024:

紐約和韋爾瑟姆,2024年11月04日(環球財經資訊) -- Dianthus Therapeutics, Inc.(納斯達克:DNTH)是一家臨床階段的生物技術公司,致力於推動下一代抗體互補治療藥物,用於治療嚴重的自身免疫性疾病。今天,公司宣佈首席執行官馬裏諾·加西亞將參加並在2024年11月和12月期間舉行的以下醫療保健投資者會議上進行企業概況展示:

  • Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MA
  • Jefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London
  • 7th Annual Evercore HealthCONx Conference on December 4 at 10:50 a.m. ET in Coral Gables, FL
  • 古根海姆醫療創新大會,於11月11日下午1:30在馬薩諸塞州波士頓舉行
  • 傑富瑞全球醫療保健大會,於11月19日上午9:00在倫敦格林尼治標準時間舉行
  • 第七屆Evercore HealthCONx大會,於12月4日上午10:50在佛羅里達州科勒爾蓋布爾斯舉行

Live webcasts of the Company's presentations at these three conferences may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website.

公司在這三個大會上的演示現場直播可在Dianthus Therapeutics網站的「新聞與事件」欄目中的投資者部分訪問。

About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

關於Dianthus Therapeutics
Dianthus Therapeutics是一家臨床階段的生物技術公司,致力於設計和提供具有改進選擇性和效力的新型頭孢單克隆抗體。總部位於紐約市和沃爾瑟姆,迪安斯由一支經驗豐富的生物技術和製藥行業高管團隊組成,他們領導着下一代抗體互補治療的開發,旨在爲患有嚴重自身免疫和炎症性疾病的人群提供革命性的藥物。

To learn more, please visit and follow us on LinkedIn.

要了解更多信息,請訪問和我們一起LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

聯繫
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。